Bioequivalence Study of Rosuvastatin Tablet

Healthy Individuals Clinical Trial

— BE  

Official title:

A Single Center, Open Label, Randomized, Single-dose, 2 Way Cross-over Study to Explore the Bioequivalence of Vaptor 20mg (Rosuvastatin) Tablet and Crestor 20mg (Rosuvastatin) Tablet Under Fasting Conditions in Healthy Male Pakistani Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05637060
• Other study ID #: CB-027-ROS-2018/Protocol/1.0
• Status: Completed
• Phase: N/A
• Start date: November 24, 2022
• Est. completion date: December 15, 2022

Study information

• Verified date: March 2023
• Source: University of Karachi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to explore the bioequivalence of Test Product Vaptor (Rosuvastatin) 20 mg Tablet with the reference product Crestor (Rosuvastatin) 20 mg tablet under fasting conditions in healthy Pakistani male subjects.

Description:

This is a single-center, open-label, randomized, single-dose, two-period, two-way, cross-over study. Subjects will receive one single dose per treatment period of Test and Reference Drugs separated by a wash-out period of 7 days. Blood samples will be taken up to 72 hours post-dose. The primary pharmacokinetic parameters will be compared for both drugs to assess the bioequivalence.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: December 15, 2022
• Est. primary completion date: December 6, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy male volunteers aged 18 to 55 years inclusive.

• Subjects with a body mass index from 18.5 to 30 kg/m2 (both inclusive).

• Subjects who are healthy as determined by routine physical examination, including vital sign monitoring (ie, blood pressure, heart rate, and temperature), 12 Lead ECG, and laboratory analysis (ie, hematology, blood biochemistry, and urinalysis)and viral serology as determined by the investigator.

• Subjects should have a negative urine test for drugs of abuse (MOP (morphine) and THC (tetrahydrocannabinol) will be tested) and alcohol breath analysis at screening and prior to each check-in.

• Subjects will be able to, understand and sign the Informed Consent Form for Medical Screening during their screening visit and Participation Informed Consent Form on study check-In day.

Exclusion Criteria:

• History of smoking (=3 cigarettes/day), alcoholism, and test for a drug of abuse, heavy pan or gutka user as judged by teeth/mouth inspection.

• Subjects with clinically relevant evidence of cardiovascular, gastrointestinal/hepatic, renal, psychiatric, respiratory, urogenital, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, drug hypersensitivity, allergy, endocrine, major surgery or other relevant diseases as revealed by medical history, physical examination, and laboratory assessments which may interfere with the absorption, distribution, metabolism or elimination of drugs or constitute a risk factor when taking study medication.

• Subject is allergic to Rosuvastatin and/or other HMG-COA inhibitors.

• Subject has received any investigational drug within 30 days.

• Subjects with salt imbalance in the blood (especially low levels of potassium or magnesium in the blood).

• Donation or loss of more than 450 mL of blood within 3 months prior to the screening.

• Ingestion of OTC drug, within 7 days of drug administration.

• History of intake of any prescribed medicine during a period of 30 days, prior to drug administration day of study.

• History of any significant illness in the last four weeks.

• Subjects with a history of renal impairment, liver disease, hypothyroidism, myopathy and rhabdomyolysis.

• Subject taking any vitamins or herbal supplements within the last 14 days of drug administration.

• Subjects who smoke and/or take nicotine in any form. Non-smoking subjects, who have previously smoked, should at least be non-smoking for 6 months prior to dosing.

• Concomitant treatment with cyclosporine, gemfibrozil, Protease Inhibitors (atazanavir and ritonavir, lopinavir and ritonavir or simeprevir), Coumarin Anticoagulant (warfarin), Niacin, Fenofibrate, Colchicine, ezetimibe, erythromycin, an oral contraceptive/ hormone replacement therapy(Ethinyl estradiol and norgestrel), fusidic acid.

• Consumption of grapefruit and/or its products within 14 days prior to the start of study.

• Subjects who test positive for syphilis (VDRL) or who are known to have serum hepatitis or who are carriers of the Hepatitis B surface antigen (HBsAg) or are carriers of antibodies to hepatitis C virus (anti-HCV) or to the human immunodeficiency virus (HIV-1 or HIV-2).

• Individuals having undergone any major surgery within 3 months prior to the start of the study, unless deemed eligible, otherwise by the Principal Investigator or whomever he may designate.

• Inability to take oral medication.

• Subjects with any condition, which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism, or elimination of drugs.

• Subjects with clinically significant abnormalities in investigations (safety assessments) as determined by the Investigator.

Related Conditions & MeSH terms

• Healthy Individuals

Intervention

Drug:
• Test Drug
One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
• Reference Drug
One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.

Locations

Country	Name	City	State
Pakistan	Muhammad Raza Shah	Karachi	Sindh

Sponsors (2)

Lead Sponsor	Collaborator
University of Karachi	The Searle Company Limited

Country where clinical trial is conducted

Pakistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	maximum plasma concentration	maximum drug concentration in plasma after dose	up to 72 hours post dose
Primary	Time to reach maximum plasma concentration	Time required for the drug to reach maximum plasma concentration	0 to 72 hours post dose
Primary	AUC (Area under concentration vs time curve)	Area under the time versus plasma drug concentration curve	0-72 hours